The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications (Q38101677)

28 August 2017

title

The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications (English)

1 reference

28 August 2017

0 references

S Madsbad

1

0 references

publication date

26 May 2013

1 reference

Diabetes, Obesity and Metabolism

28 August 2017

published in

1 reference

28 August 2017

volume

16

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

9-21

1 reference

Weight loss reduces the risk for symptomatic knee osteoarthritis in women. The Framingham Study

28 August 2017

cites work

1 reference

Arterial destiffening with weight loss in overweight and obese middle-aged and older adults

21 January 2018

1 reference

The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study

21 January 2018

1 reference

A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study

21 January 2018

1 reference

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

Medicare's search for effective obesity treatments: diets are not the answer

21 January 2018

1 reference

Bariatric surgery: risks and rewards

21 January 2018

1 reference

Anti-obesity drugs: a review about their effects and their safety

21 January 2018

1 reference

The obesity epidemic: pharmacological challenges

21 January 2018

1 reference

Minireview: Gut peptides: targets for antiobesity drug development?

21 January 2018

1 reference

Signals that influence food intake and body weight

21 January 2018

1 reference

Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety.

21 January 2018

1 reference

Biology of incretins: GLP-1 and GIP

21 January 2018

1 reference

The Physiology of Glucagon-like Peptide 1

21 January 2018

1 reference

Role of the Prohormone Convertase PC3 in the Processing of Proglucagon to Glucagon-like Peptide 1

21 January 2018

1 reference

Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man

21 January 2018

1 reference

Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients

21 January 2018

1 reference

Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L cells

21 January 2018

1 reference

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

21 January 2018

1 reference

Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors

21 January 2018

1 reference

International Union of Pharmacology. XXXV. The glucagon receptor family

21 January 2018

1 reference

Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain

21 January 2018

1 reference

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

21 January 2018

1 reference

Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis

21 January 2018

1 reference

Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia

21 January 2018

1 reference

Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans

21 January 2018

1 reference

Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans

21 January 2018

1 reference

Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass

21 January 2018

1 reference

A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans

21 January 2018

1 reference

The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem

21 January 2018

1 reference

A role for glucagon-like peptide-1 in the central regulation of feeding

21 January 2018

1 reference

Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats

21 January 2018

1 reference

Hepatic-portal vein infusions of glucagon-like peptide-1 reduce meal size and increase c-Fos expression in the nucleus tractus solitarii, area postrema and central nucleus of the amygdala in rats.

21 January 2018

1 reference

The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation

21 January 2018

1 reference

The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway

21 January 2018

1 reference

Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4

21 January 2018

1 reference

A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.

21 January 2018

1 reference

Inhibitory effect of GLP-1 on gastric motility persists after vagal deafferentation in pigs

21 January 2018

1 reference

Vagally mediated effects of glucagon-like peptide 1: in vitro and in vivo gastric actions

21 January 2018

1 reference

Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms

21 January 2018

1 reference

Liraglutide: short-lived effect on gastric emptying -- long lasting effects on body weight

21 January 2018

1 reference

Exenatide reduces food intake and activates the enteric nervous system of the gastrointestinal tract and the dorsal vagal complex of the hindbrain in the rat by a GLP-1 receptor

21 January 2018

1 reference

Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans

21 January 2018

1 reference

Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment

21 January 2018

1 reference

Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes

21 January 2018

1 reference

The beta-agonist controversy

21 January 2018

1 reference

Peripheral versus central cardiorespiratory effects of morphine

21 January 2018

1 reference

Alterations in energy balance following exenatide administration

21 January 2018

1 reference

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line

21 January 2018

1 reference

Glucagon-like peptide-1 7-36: a physiological incretin in man.

21 January 2018

1 reference

Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity

21 January 2018

1 reference

Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients

21 January 2018

1 reference

Attenuated GLP-1 secretion in obesity: cause or consequence?

21 January 2018

1 reference

Glucagon-like peptide-1 release and satiety after a nutrient challenge in normal-weight and obese subjects

21 January 2018

1 reference

Influence of BMI and gender on postprandial hormone responses

21 January 2018

1 reference

Distal small bowel hormones: correlation with fasting antroduodenal motility and gastric emptying.

21 January 2018

1 reference

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients

21 January 2018

1 reference

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus

21 January 2018

1 reference

Inhibition of carbohydrate-mediated glucagon-like peptide-1 (7-36)amide secretion by circulating non-esterified fatty acids

21 January 2018

1 reference

GLP-1 and energy balance: an integrated model of short-term and long-term control

21 January 2018

1 reference

Molecular physiology of weight regulation in mice and humans

21 January 2018

1 reference

Obesity and leptin resistance: distinguishing cause from effect

21 January 2018

1 reference

Role of leptin in the regulation of glucagon-like peptide-1 secretion

21 January 2018

1 reference

Leptin receptor expression in hindbrain Glp-1 neurons regulates food intake and energy balance in mice

21 January 2018

1 reference

Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation

21 January 2018

1 reference

Effects of leptin replacement alone and with exendin-4 on food intake and weight regain in weight-reduced diet-induced obese rats

21 January 2018

1 reference

Association of body mass and brain activation during gastric distention: implications for obesity

21 January 2018

1 reference

Insulin resistance and pancreatic beta cell failure

21 January 2018

1 reference

How strong is the association between abdominal obesity and the incidence of type 2 diabetes?

21 January 2018

1 reference

Is all fat the same? The role of fat in the pathogenesis of the metabolic syndrome and type 2 diabetes mellitus

21 January 2018

1 reference

Point: visceral adiposity is causally related to insulin resistance

21 January 2018

1 reference

Physical activity, body mass index, and risk of type 2 diabetes in patients with normal or impaired glucose regulation

21 January 2018

1 reference

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

Defects in GLP-1 response to an oral challenge do not play a significant role in the pathogenesis of prediabetes

21 January 2018

1 reference

Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance

21 January 2018

1 reference

Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake

21 January 2018

1 reference

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

21 January 2018

1 reference

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients

21 January 2018

1 reference

Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes

21 January 2018

1 reference

Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus

21 January 2018

1 reference

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

21 January 2018

1 reference

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

21 January 2018

1 reference

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects

21 January 2018

1 reference

Impairment of GLP1-induced insulin secretion: role of genetic background, insulin resistance and hyperglycaemia

21 January 2018

1 reference

Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of Type II (non-insulin-dependent) diabetic parents: evidence of several aberrations

21 January 2018

1 reference

Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes

21 January 2018

1 reference

Effects of glucagon-like peptide-1(7-36)amide on motility and sensation of the proximal stomach in humans

21 January 2018

1 reference

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

21 January 2018

1 reference

DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials

21 January 2018

1 reference

Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review

21 January 2018

1 reference

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

21 January 2018

1 reference

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

21 January 2018

1 reference

Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes

21 January 2018

1 reference

Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes

21 January 2018

1 reference

Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes

21 January 2018

1 reference

Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes

21 January 2018

1 reference

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

21 January 2018

1 reference

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

21 January 2018

1 reference

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

21 January 2018

1 reference

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

21 January 2018

1 reference

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study

21 January 2018

1 reference

DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes

21 January 2018

1 reference

Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus

21 January 2018

1 reference

Pharmaceutical cost savings of treating obesity with weight loss medications

21 January 2018

1 reference

Effects of lifestyle intervention on health care costs: Improving Control with Activity and Nutrition (ICAN).

21 January 2018

1 reference

PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans.

21 January 2018

1 reference

Outstanding Scientific Achievement Award Lecture 2011: defeating diabesity: the case for personalized combinatorial therapies

21 January 2018

1 reference

The effect of a very low calorie diet on insulin sensitivity, beta cell function, insulin clearance, incretin hormone secretion, androgen levels and body composition in obese young women

21 January 2018

1 reference

Reduced Incretin Effect in Type 2 Diabetes

21 January 2018

1 reference

The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans

21 January 2018

1 reference

Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms

21 January 2018

1 reference

Effects of glucagon-like peptide 1 (7-36 amide) on whole-body protein metabolism in healthy man

21 January 2018

1 reference

The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity

21 January 2018

1 reference

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12119

1 reference

28 August 2017

1 reference